Drosophila eye color mutants as therapeutic tools for Huntington disease

Fly

Volumn 6, Issue 2, 2012, Pages 117-120

  Green, Edward W ^a   Campesan, Susanna ^a   Breda, Carlo ^a   Sathyasaikumar, Korrapati V ^b   Muchowski, Paul J ^c   Schwarcz, Robert ^b   Kyriacou, Charalambos P ^a   Giorgini, Flaviano ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c GLADSTONE INSTITUTE OF NEUROLOGICAL DISEASE   (United States)

Author keywords

Huntington disease; IDO; KMO; Kynurenine pathway; Neurodegeneration; TDO

Indexed keywords

EID: 84862488604     PISSN: 19336934     EISSN: 19336942     Source Type: Journal    
DOI: 10.4161/fly.19999     Document Type: Article

References (25)

1. Thevandavakkam MA, Schwarcz R, Muchowski PJ, Giorgini F. Targeting kynurenine-3-monooxygenase (KMO): implications for therapy in Huntington's disease. CNS Neurol Disord Drug Targets 2010; 9:791-800; PMID:20942784.
2. Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis 2004; 17:455-61; http://dx.doi. org/10.1016/j.nbd.2004.07.006. PMID:15571981.
3. Beal MF. Mechanisms of excitotoxicity in neurologic diseases. FASEB J 1992; 6:3338-44; PMID:1464368.
4. Schwarcz R, Whetsell WO Jr, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 1983; 219:316-8; PMID:6849138; http://dx.doi. org/10.1126/science.6849138.
5. Guidetti P, Schwarcz R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur J Neurosci 1999; 11:3857-63; PMID:10583474; http://dx.doi.org/10.1046/j.1460-9568.1999.00806.x.
6. Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease. Exp Neurol 2006; 197:31-40; http://dx.doi.org/10.1016/j.expneurol.2005.07.004; PMID:16099455.
7. Guidetti P, Schwarcz R. 3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease? Adv Exp Med Biol 2003; 527:137-45; PMID:15206726; http://dx.doi. org/10.1007/978-1-4615-0135-0_16.
8. Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ. A genomic screen in yeast implicates kynurenine-3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 2005; 37:526-31;http://dx.doi.org/10.1038/ng1542; PMID:15806102.
9. Campesan S, Green EW, Breda C, Sathyasaikumar KV, Muchowski PJ, Schwarcz R, et al. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr Biol 2011; 21:961-6; http://dx.doi.org/10.1016/j. cub.2011.04.028; PMID:21636279.
10. Bernt L. The tryptophan→ommochrome pathway in insects. In: Advances in Insect Physiology: Academic Press 117-246.
11. Tearle R. Tissue specific effects of ommochrome pathway mutations in Drosophila melanogaster. Genet Res 1991; 57:257-66; PMID:1909678; http://dx.doi. org/10.1017/S0016672300029402.
12. Tartof KD. Interacting gene systems: I. The regulation of tryptophan pyrrolase by the vermilion-suppressor of vermilion system in Drosophila. Genetics 1969; 62:781-95; PMID:5384490.
13. Searles LL, Ruth RS, Pret AM, Fridell R A, Ali AJ. Structure and transcription of the Drosophila melanogaster vermilion gene and several mutant alleles. Mol Cell Biol 1990; 10:1423-31; PMID:2108317.
14. Dietzl G, Chen D, Schnorrer F, Su KC, Barinova Y, Fellner M, et al. A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature 2007; 448:151-6; http://dx.doi. org/10.1038/nature05954;PMID:17625558.
15. Amori L, Guidetti P, Pellicciari R, Kajii Y, Schwarcz R. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J Neurochem 2009; 109:316-25; http://dx.doi.org/10.1111/j.1471-4159.2009.05893.x; PMID:19226371.
16. Röver S, Cesura AM, Huguenin P, Kettler R, Szente A. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as highaffinity inhibitors of kynurenine-3-hydroxylase. J Med Chem 1997; 40:4378-85; http://dx.doi. org/10.1021/jm970467t; PMID:9435907.
17. Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 2011; 145:863-74; http://dx.doi.org/10.1016/j.cell.2011.05.020; PMID:21640374.
18. Mason RP, Giorgini F. Modeling Huntington disease in yeast: Perspectives and future directions. Prion 2011; 5:5; PMID:22052350; http://dx.doi. org/10.4161/pri.5.4.18005.
19. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects and clinical opportunities. J Pharmacol Exp Ther 2002; 303:1-10; http://dx.doi.org/10.1124/jpet.102.034439; PMID:12235226.
20. González A, Varo N, Alegre E, Díaz A, Melero I. Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach. Adv Clin Chem 2008; 45:155-97; PMID:18429497; http://dx.doi.org/10.1016/S0065-2423(07)00007-8.
21. Möller T. Neuroinf lammation in Huntington's disease. J Neural Transm 2010; 117:1001-8; http: //dx.doi.org/10.1007/s00702-010-0430-7; PMID:20535620.
22. Sathyasaikumar KV, Stachowski EK, Amori L, Guidetti P, Muchowski PJ, Schwarcz R. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease. J Neurochem 2010; 113:1416-25; http://dx.doi.org/10.1111/j.1471-4159.2010.06675.x; PMID:20236387.
23. Evans JM, Day JP, Cabrero P, Dow JA, Davies SA. new role for a classical gene: white transports cyclic GMP. J Exp Biol 2008; 211:890-9; http://dx.doi. org/10.1242/jeb.014837; PMID:18310115.
24. Plangár I, Zádori D, Klivényi P, Toldi J, Vécsei Targeting the kynurenine pathway-related alterations in Alzheimer's disease: a future therapeutic strategy. J Alzheimers Dis 2011; 24:199-209; http://dx.doi. org/10.3233/JAD-2011-110131; PMID:21441658.
25. Grégoire L, Rassoulpour A, Guidetti P, Samadi Bédard PJ, Izzo E, et al. Prolonged kynurenine-3-hydroxylase inhibition reduces development of levodopa induced dyskinesias in parkinsonian monkeys. Behav Brain Res 2008; 186:161-7; http://dx.doi. org/10.1016/j.bbr.2007.08.007; PMID:17868931.